Cellectis Inc - Company & Market Research Reports

Cellectis is a gene-editing company that develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company designs novel products including immune therapies for cancer and enzymes which can add DNA at targeted places in genomes. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies which develop in acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia. Cellectis S.A. was founded in 1999 and is based in Paris, France.

From
From
From
From
From
From
BCMA Targeted Therapies, 2017-2030 - Product Thumbnail Image

BCMA Targeted Therapies, 2017-2030

  • Report
  • 143 Pages
From
From
From
From
From
From
Loading Indicator
adroll